My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 448

    1.

    Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.

    Wärnberg F, White D, Anderson E, Knox F, Clarke RB, Morris J, Bundred NJ.

    Breast Cancer Res. 2006;8(2):R21. Epub 2006 Apr 12.PMID: 16611371 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

    Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR.

    Clin Cancer Res. 2001 Nov;7(11):3544-50.PMID: 11705875 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

    End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C.

    Cancer Res. 2001 Jan 1;61(1):131-7.PMID: 11196150 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ.

    Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ.

    Cancer Res. 2000 Aug 1;60(15):4284-8.PMID: 10945643 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.

    Martin LA, Head JE, Pancholi S, Salter J, Quinn E, Detre S, Kaye S, Howes A, Dowsett M, Johnston SR.

    Mol Cancer Ther. 2007 Sep;6(9):2458-67.PMID: 17876043 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

    Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P.

    Breast Cancer Res. 2005;7(4):R422-35. Epub 2005 Apr 4.PMID: 15987447 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.

    Caraglia M, Marra M, Viscomi C, D'Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, Tassone P, Venuta S, Abbruzzese A, Tagliaferri P.

    Int J Cancer. 2007 Nov 15;121(10):2317-30. Erratum in: Int J Cancer. 2008 Apr 15;122(8):1922. PMID: 17657738 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.

    Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y.

    Breast Cancer Res. 2005;7(6):R1097-110. Epub 2005 Nov 9.PMID: 16457690 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells.

    Radestock Y, Hoang-Vu C, Hombach-Klonisch S.

    Breast Cancer Res. 2008;10(4):R71. Epub 2008 Aug 21.PMID: 18718015 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.

    Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ.

    Clin Cancer Res. 2001 Mar;7(3):691-703.PMID: 11297266 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.

    Namba R, Young LJ, Maglione JE, McGoldrick ET, Liu S, Wurz GT, DeGregorio MW, Borowsky AD, MacLeod CL, Cardiff RD, Gregg JP.

    Breast Cancer Res. 2005;7(6):R881-9. Epub 2005 Sep 13.PMID: 16280035 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast.

    Holland PA, Knox WF, Potten CS, Howell A, Anderson E, Baildam AD, Bundred NJ.

    J Natl Cancer Inst. 1997 Jul 16;89(14):1059-65.PMID: 9230888 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Growth inhibitory effects of diallyl disulfide on human breast cancer cell lines.

    Nakagawa H, Tsuta K, Kiuchi K, Senzaki H, Tanaka K, Hioki K, Tsubura A.

    Carcinogenesis. 2001 Jun;22(6):891-7.PMID: 11375895 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.

    Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ.

    Br J Cancer. 2007 Feb 26;96(4):575-82. Epub 2007 Feb 6.PMID: 17285134 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.

    Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC.

    Br J Cancer. 2007 Apr 23;96(8):1204-15. Epub 2007 Mar 27.PMID: 17387344 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.

    Rolland D, Camara-Clayette V, Barbarat A, Salles G, Coiffier B, Ribrag V, Thieblemont C.

    Cancer Chemother Pharmacol. 2008 Apr;61(5):855-63. Epub 2007 Jul 18.PMID: 17639395 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice.

    Van den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee D.

    Eur J Cancer. 1997 Jun;33(7):1108-13.PMID: 9376191 [PubMed - indexed for MEDLINE]Related articles

    18.

    Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway.

    Kasper G, Reule M, Tschirschmann M, Dankert N, Stout-Weider K, Lauster R, Schrock E, Mennerich D, Duda GN, Lehmann KE.

    BMC Cancer. 2007 Jan 17;7:12.PMID: 17233884 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice.

    Su Y, Vanderlaag K, Ireland C, Ortiz J, Grage H, Safe S, Frankel AE.

    Breast Cancer Res. 2007;9(4):R56.PMID: 17764562 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

    Taylor SA, Marrinan CH, Liu G, Nale L, Bishop WR, Kirschmeier P, Liu M, Long BJ.

    Gynecol Oncol. 2008 Apr;109(1):97-106. Epub 2008 Jan 31.PMID: 18237771 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk